Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 1/20 | 0.42 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.42 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.42 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 4/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 3/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29833737 | 1.00 | ANPEP (0.42) | ANPEPGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL19420453 | 1.00 | ANPEP (0.42) | ANPEPGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL4168243 | 1.00 | ANPEP (0.42) | ANPEPGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL8049751 | 1.00 | ANPEP (0.42) | ANPEPGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL3867845 | 1.00 | ANPEP (0.42) | ANPEPGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL562559 | 1.00 | ANPEP (0.42) | ANPEPGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL5271544 | 1.00 | ANPEP (0.42) | ANPEPGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL5166344 | 0.94 | ANPEP (0.39) | ANPEPGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL6550318 | 0.83 | KDM1A (0.48) | ANPEPGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL8077009 | 0.81 | ACHE (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030022335-A1 | Novel polypeptides and methods for their use | UNIVERSITY OF IOWA RESEARCH FOUNDATION | 2003-01-30 | — | — | US | claimed |
| US-6171832-B1 | FERMENTING STARTING MATERIAL IN CULTURE, RECOVERING PRODUCT; BY PRODUCT INHIBITION; CHEMICAL INTERMEDIATE FOR SYNTHESIS OF INDINAVIR, A POTENT HUMAN IMMUNODEFICIENCY VIRUS PROTEASE INHIBITOR | MERCK & CO., INC. | 2001-01-09 | — | — | US | claimed |
| US-6165777-A | Process for the resolution of cis 1,2-indane diols using Pseudomonas putida | ZENECA LIMITED (GB) | 2000-12-26 | — | — | US | claimed |
| WO-2000037480-A1 | NOVEL NAPHTHALENE DIOXYGENASE AND METHODS FOR THEIR USE | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2000-06-29 | — | — | WO | claimed |
| EP-0784697-B1 | BACTERIAL PROCESS FOR THE RESOLUTION OF RACEMIC CIS-DIOLS | AVECIA LTD (GB) | 2000-05-03 | — | — | EP | claimed |
| EP-0874059-A2 | PROCESSES FOR PRODUCING INDANE DERIVATIVES | NIPPON STEEL CHEMICAL CO., LTD. (JP) | 1998-10-28 | — | — | EP | claimed |
| EP-0874059-A1 | PROCESSES FOR PRODUCING INDANE DERIVATIVES | NIPPON STEEL CHEMICAL CO., LTD. (JP) | 1998-10-28 | — | — | EP | claimed |
| US-5811294-A | Production of optically active 1,2-dihydroxyindance derivatives by asymetric assimilation | ZENECA LIMITED (GB) | 1998-09-22 | — | — | US | claimed |
| EP-0784697-A1 | BACTERIAL PROCESS FOR THE RESOLUTION OF RACEMIC CIS-DIOLS | ZENECA LIMITED (GB) | 1997-07-23 | — | — | EP | claimed |
| WO-1996011282-A1 | BACTERIAL PROCESS FOR THE RESOLUTION OF RACEMIC CIS-DIOLS | ZENECA LIMITED (GB) | 1996-04-18 | — | — | WO | claimed |
| EP-0658537-A1 | Method of producing cis-1-aminoindan-2-ol | ICHIKAWA GOSEI CHEMICAL CO., LTD. (JP) | 1995-06-21 | — | — | EP | claimed |
| JP-11075888-A | — | — | None | — | — | JP | disclosed |
| US-10906033-B2 | Synthesis and application of chiral substituted polyvinylpyrrolidinones | KANSAS STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2021-02-02 | — | — | US | disclosed |
| US-10906033-B2 | Synthesis and application of chiral substituted polyvinylpyrrolidinones | KANSAS STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2021-02-02 | — | — | US | disclosed |
| US-20200306737-A1 | SYNTHESIS AND APPLICATION OF CHIRAL SUBSTITUTED POLYVINYLPYRROLIDINONES | KANSAS STATE UNIVERSITY RESEARCH FOUNDATION | 2020-10-01 | — | — | US | disclosed |
| US-5508404-A | 3-PYRIDINE CARBOXALDEHYDE AS REACTANT IN PRESENCE OF EXCESS REDUCING AGENT YIELDING HIV PROTEASE INHIBITOR | MERCK & CO., INC. (US) | 1996-04-16 | — | — | US | disclosed |
| US-5489710-A | AMINATION BY MIXING WITH NITRILE SOLVENT, ACIDIFICATION AND HYDROLYZING WITH WATER | MERCK & CO., INC. (US) | 1996-02-06 | — | — | US | disclosed |
| WO-1995024374-A1 | REGIOSPECIFIC PROCESSES TO MAKE CIS-1-AMINO-2-ALKANOL FROM DIOL OR HALOHYDRIN | MERCK & CO., INC. (US) | 1995-09-14 | — | — | WO | disclosed |
| US-5449830-A | Enzyme inhibitors for protease encoded for HIV | MARCK & CO., INC. (US) | 1995-09-12 | — | — | US | disclosed |
| EP-0658537-A1 | Method of producing cis-1-aminoindan-2-ol | ICHIKAWA GOSEI CHEMICAL CO., LTD. (JP) | 1995-06-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200306737-A1 | SYNTHESIS AND APPLICATION OF CHIRAL SUBSTITUTED POLYVINYLPYRROLIDINONES | POLRMT, CNBP, DHPS | ANPEP 1526/4885GRIN2D 4610/4885GRIN3B 4689/4885 |
| US-10906033-B2 | Synthesis and application of chiral substituted polyvinylpyrrolidinones | POLRMT, CNBP, DHPS | ANPEP 1526/4885GRIN2D 4610/4885GRIN3B 4689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.